Dr Svoboda on the Efficacy of Armored huCART19-IL18 in R/R Lymphoma
Jakub Svoboda, MD, discusses outcomes with armored huCART19-IL18 in patients with previously treated relapsed/refractory lymphomas that have progressed.
Jakub Svoboda Hospital Of The University Pennsylvania Data Safety Monitoring Committee Abramson Cancer Center Lymphoma Tumor Board Case Conference
Source: onclive.com